{"date":"2025-11-16","count":6,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6610-2025-11-16-2253-frb2l8","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2025-11-16","time":"22:53:59","subject":"公告本公司暫停召開114年11月18日之法人說明會","clause":"第44款","fact_date":"2025-11-16","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2025-11-16 22:53，「公告本公司暫停召開114年11月18日之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6499-2025-11-16-2215-u4fp7i","company_id":"6499","company":"益安","market":"上櫃","industry":"生技醫療","date":"2025-11-16","time":"22:15:55","subject":"攝護腺微創治療醫材Urocross Expander System主系統正式向美國FDA提交510(k)上市許可申請","clause":"第10款","fact_date":"2025-11-14","cite_as":"公開資訊觀測站重大訊息：益安（6499），2025-11-16 22:15，「攝護腺微創治療醫材Urocross Expander System主系統正式向美國FDA提交510(k)上市許可申請」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6610-2025-11-16-2126-8ojr6i","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2025-11-16","time":"21:26:27","subject":"公告本公司 NORA520 治療產後憂鬱症 (PPD) 第二期臨床試驗重要療效指標結果","clause":"第8款","fact_date":"2025-11-16","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2025-11-16 21:26，「公告本公司 NORA520 治療產後憂鬱症 (PPD) 第二期臨床試驗重要療效指標結果」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6610-2025-11-16-2126-1rfb93o","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2025-11-16","time":"21:26:07","subject":"公告本公司召開重大訊息記者會及新聞稿內容","clause":"第44款","fact_date":"2025-11-16","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2025-11-16 21:26，「公告本公司召開重大訊息記者會及新聞稿內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2025-11-16-1920-1kawwiu","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2025-11-16","time":"19:20:42","subject":"代子公司Belite Bio (Swiss) AG公告轉投資設立日本子公司及指派轉投資子公司董事事宜","clause":"第44款","fact_date":"2025-11-14","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2025-11-16 19:20，「代子公司Belite Bio (Swiss) AG公告轉投資設立日本子公司及指派轉投資子公司董事事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-11-16-1415-17pslkv","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-11-16","time":"14:15:16","subject":"本公司OBI-902 TROP2 ADC新藥獲美國食品藥物管理局審核通過治療膽管癌的「孤兒藥」資格認定","clause":"第10款","fact_date":"2025-11-16","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-11-16 14:15，「本公司OBI-902 TROP2 ADC新藥獲美國食品藥物管理局審核通過治療膽管癌的「孤兒藥」資格認定」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}